반응식
[CH2:1]([C:13]1[NH:17][N:16]=[N:15][N:14]=1)[CH2:2][CH2:3][CH2:4][CH2:5][CH2:6][CH2:7][CH2:8][CH2:9][CH2:10][CH2:11][CH3:12].C(C1NN=NN=1)CCCCCCCCC.[CH2:33]([O:35][C:36](=[O:51])[CH:37](Br)[CH2:38][CH2:39][CH2:40][CH2:41][CH2:42][CH2:43][CH2:44][CH2:45][CH2:46][CH2:47][CH2:48][CH3:49])[CH3:34].BrC1C=CC=CC=1CC(OCC)=O>>[CH2:1]([C:13]1[N:14]=[N:15][N:16]([CH:37]([CH2:38][CH2:39][CH2:40][CH2:41][CH2:42][CH2:43][CH2:44][CH2:45][CH2:46][CH2:47][CH2:48][CH3:49])[C:36]([O:35][CH2:33][CH3:34])=[O:51])[N:17]=1)[CH2:2][CH2:3][CH2:4][CH2:5][CH2:6][CH2:7][CH2:8][CH2:9][CH2:10][CH2:11][CH3:12]참가 물질
5
실험 절차
When in the general procedure of Example 71 an appropriate amount of 5-dodecyl-1H-tetrazole was substituted for 5-decyl-1H-tetrazole and an appropriate amount of ethyl-2-bromomyristate was substituted for ethyl 2-bromophenylacetate, the title compound was obtained. 1H NMR (CDCl3): δ5.47-5.41 (m, 1H); 4.25-4.17 (q, 2H); 2.94-2.88 (t, 2H); 2.45-2.26 (m, 2H); 1.82-1.65 (m, 2H); 1.33-1.20 (m, 41H); and 0.90-0.85 (t, 6H) ppm.
출처 및 근거
- ORD 기록
- ord-9ab3c58b940544309debba30e344a990
- 출처 데이터셋
- uspto-grants-1997_07
- 특허 번호
- US05646170
연결된 노트
불러오는 중…